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Abstract. Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2
3/100.000/year  in  developed  countries.  With  modern  multi
optionally  combined  with  radiotherapy  (RT),  80%  to  90%  of  HL  patients  achieve  long
remission and can be considered cured. However, current standard approaches bear a considerable 
risk for the development of treatment
research in HL is reducing the incidence of these late 
chronic fatigue and therapy-related myelodysplastic syndrome/acute myeloid leukemia (t
AML). In previous analyses, t-MDS/t
prognosis. Nearly all patients died rapidly after diagnosis. However, more recent analyses indicated 
an  improved  outcome  among  patients  with  t
leukemic treatment and allogeneic stem cell transplantation (aSCT). This article gives an over
of  recent  reports  on  the  incidence  and  the  treatment  of  t
describes the efforts currently made to reduce the risk to develop this severe late effect.  
Introduction. Hodgkin  lymphoma  (HL)  is  a 
malignancy of the lymphatic system with an incidence 
of  2-3/100.000/year  in  Europe  and  North  America.
The  disease  generally  occurs  in  all  age  groups  but 
young adults are most often affected.
substantial treatment improvements in the past decades 
including  the  introduction  of  highly  effective  multi
agent chemotherapy protocols and the optimization of 
radiation fields and doses, HL has become one of the 
best  curable  adult  malignancies.  Irrespective  of  the 
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Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2
3/100.000/year  in  developed  countries.  With  modern  multi-agent  chemotherapy  protocols 
optionally  combined  with  radiotherapy  (RT),  80%  to  90%  of  HL  patients  achieve  long
remission and can be considered cured. However, current standard approaches bear a considerable 
risk for the development of treatment-related late effects. Thus, one major focus of current clinical 
research in HL is reducing the incidence of these late effects that include heart failure, infertility, 
related myelodysplastic syndrome/acute myeloid leukemia (t
MDS/t-AML after treatment for HL was associated with a poor 
tients died rapidly after diagnosis. However, more recent analyses indicated 
an  improved  outcome  among  patients  with  t-MDS/t-AML  who  are  eligible  for  modern  anti
leukemic treatment and allogeneic stem cell transplantation (aSCT). This article gives an over
of  recent  reports  on  the  incidence  and  the  treatment  of  t-MDS/t-AML  after  HL  therapy  and 
describes the efforts currently made to reduce the risk to develop this severe late effect.  
Hodgkin  lymphoma  (HL)  is  a 
malignancy of the lymphatic system with an incidence 
3/100.000/year  in  Europe  and  North  America.
1
The  disease  generally  occurs  in  all  age  groups  but 
young adults are most often affected.
2 As a result of 
substantial treatment improvements in the past decades 
including  the  introduction  of  highly  effective  multi-
agent chemotherapy protocols and the optimization of 
radiation fields and doses, HL has become one of the 
ncies.  Irrespective  of  the 
initial stage, 80% to 90% of patients achieve long
remission  (Figure  1).
3-5 This  has  led
growing number of HL survivors. Since these survivors 
often suffer from treatment-
heart failure, infertility, chronic fatigue and secondary 
malignancies,  reducing  the  frequency  of  long
sequelae without compromising treatment efficacy has 
become one of the major challenges of current clinical 
research  in  HL.
6-9 Therapy
syndrome/acute  myeloid  leukemia  (t
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Hodgkin lymphoma (HL) is a malignancy of the lymphatic system with an incidence of 2-
agent  chemotherapy  protocols 
optionally  combined  with  radiotherapy  (RT),  80%  to  90%  of  HL  patients  achieve  long-term 
remission and can be considered cured. However, current standard approaches bear a considerable 
related late effects. Thus, one major focus of current clinical 
effects that include heart failure, infertility, 
related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/t-
AML after treatment for HL was associated with a poor 
tients died rapidly after diagnosis. However, more recent analyses indicated 
AML  who  are  eligible  for  modern  anti-
leukemic treatment and allogeneic stem cell transplantation (aSCT). This article gives an overview 
AML  after  HL  therapy  and 
describes the efforts currently made to reduce the risk to develop this severe late effect.  
initial stage, 80% to 90% of patients achieve long-term 
This  has  led to  a  steadily 
growing number of HL survivors. Since these survivors 
-related late effects such as 
heart failure, infertility, chronic fatigue and secondary 
malignancies,  reducing  the  frequency  of  long-term 
omising treatment efficacy has 
become one of the major challenges of current clinical 
Therapy-related  myelodysplastic 
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Figure 1: Progression-free survival among Hodgkin lymphoma patients treated in British Columbia during the indicated decades (adopted 
from Connors, Hematology Am Soc Hematol Educ Program, 2003)
represents one of the most severe late effects after HL 
treatment and has been associated with a particularly 
poor prognosis. Nearly all patients died rapidly after 
diagnosis.
10
However,  incidence  and  prognosis  of  t-MDS/t-
AML after  HL treatment may change in  the  coming 
years.  Response-adapted  treatment  strategies  that  are 
currently  being  evaluated  in  clinical  trials  will 
potentially  lead  to  a  decrease  of  cumulative 
chemotherapy  and  radiation  doses  in  many  HL 
patients. Thus, the risk to develop t-MDS/t-AML will 
be reduced. Improvements in the treatment of t-MDS/t-
AML mainly due to the increased availability and the 
more  efficient  use  of  allogeneic  stem  cell 
transplantation (aSCT)  will  probably  have  a  positive 
impact on the prognosis of the mostly young patients 
diagnosed with t-MDS/t-AML after HL treatment.
This review aims at giving an overview of relevant 
analyses on the development, incidence, clinical course 
and  treatment  of  t-MDS/t-AML  after  HL.  Current 
strategies to reduce the risk of t-MDS/t-AML are also 
discussed. 
Leukemogenic  drugs  in  HL  treatment.  ABVD 
(adriamycin, bleomycin, vinblastine, dacarbazine) and 
BEACOPP  (bleomycin,  etoposide,  adriamycin, 
cyclophosphamide,  vincristine,  procarbazine, 
prednisone)  are  the  chemotherapy  protocols  most 
widely used for the first-line treatment of adult patients 
with HL.
11-12 Both regimens include alkylating agents, 
namely  dacarbazine  in  the  ABVD  protocol  and 
cyclophosphamide and procarbazine in the BEACOPP 
schema.  Alkylating  agents  are  known  to  be 
leukemogenic.  Secondary  leukemias  induced  by  this 
drug  class  mostly  occur  three  to  eight  years  after 
exposition and are often preceded by a pre-leukemic 
phase  that  is  characterized  by  myelodysplasia. 
Chromosome  aberrations  are  common  in  t-MDS/t-
AML  induced  by  alkylating  agents.  Losses  of 
chromosome 5 or chromosome 7 as well as deletions of 
the  long  arm  of  the  same  chromosomes  are  most 
frequently observed.
13
Topoisomerase-II-inhibitors represent another drug 
class with leukemogenic potential used in the treatment 
of  HL. Particularly  etoposide  is  frequently  applied. 
Besides first-line protocols such as BEACOPP it is also 
contained in  high-dose  regimens  used in  the  salvage 
setting,  BEAM (BCNU,  etoposide, ara-c,  melphalan) 
for instance.
12,14 In comparison with alkylating agents, 
secondary  leukemias  induced  by  topoisomerase-II-
inhibitors  are  characterized  by  a  more  rapid 
development after exposure. Thus, the median latency 
period  between  treatment  with  topoisomerase-II-
inhibitors and diagnosis of secondary leukemia is about 
two years; a pre-leukemic phase with myelodysplastic 
alterations in the bone marrow is usually not observed. 
However,  similar  to  alkylating  agents,  chromosomal 
aberrations are also often found in secondary leukemias Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
after  treatment  with  topoisomerase-II-inhibitors. 
Translocations  at  the  myeloid-lymphoid  leukemia 
(MLL) gene locus 11q23 represent the most frequent 
aberration.
13
Incidence, clinical course and treatment of t-MDS/t-
AML in HL patients. The two most recent reports on 
t-MDS/t-AML in HL patients come from the German 
Hodgkin Study Group (GHSG). Josting and colleagues 
screened 5.411 patients treated within GHSG clinical 
trial  protocols  between  1981  and  1998  for  the 
development of t-MDS/t-AML. Results were published 
in  2003.  At  a  median  follow-up  of  55  months,  46 
patients had developed t-MDS/t-AML; the cumulative 
risk to develop t-MDS/t-AML was 1%. In the majority 
of  cases,  HL  treatment  had  consisted  of  ABVD  or 
ABVD-based  chemotherapy  protocols mostly 
combined with consolidating radiotherapy (RT); some 
patients  had  received  BEACOPP.  The  median  time 
interval between HL treatment and the diagnosis of t-
MDS/t-AML  was  12.5  months.  An  evaluation  of 
cytogenetic changes was performed in 15 patients. All 
of them had chromosomal abnormalities. Aberrations 
affecting  chromosome  5  or  chromosome  7  and  the 
presence  of  an  MLL-rearrangement  were  most  often 
observed. Clinical outcome of patients with t-MDS/t-
AML included in this analysis was poor with a median 
overall survival (OS) of only four months for the whole 
patient group and ten months for the nine patients who 
underwent  aSCT.  At  24  months,  freedom  from 
treatment  failure  and  OS  rates  were  2%  and  8%, 
respectively (Figure 2).
10
An  update  analysis  including  patients  treated 
according to GHSG trial protocols between 1993 and 
2009  was  presented  in  abstract  form  in  2010.  In 
contrast to the report from Josting and colleagues, an 
increased portion of patients included in this analysis 
had  received  the  intensive  BEACOPPescalated protocol 
representing the current standard of care for younger 
patients with advanced HL within the GHSG. A total 
of 11891 patients were screened for the occurrence of 
secondary  myeloid  neoplasms.  Therapy-related 
MDS/AML  had  been  diagnosed  in  99  of  them. 
However,  13  patients  were  excluded  from  final 
analysis due to a concurrent event prior to the diagnosis 
of t-MDS/t-AML so that 86 patients were eventually 
taken into account. Since the intensity of HL treatment 
appears  to  have  a  significant  impact  on  the  risk  to 
develop  t-MDS/t-AML,  patients  were  divided  into 
three  subgroups.  Patients  from  the  first  group  had 
received  no  BEACOPPescalated - containing 
chemotherapy,  patients  from  the  second  group  had 
received less than four cycles of BEACOPPescalated and 
patients from the third group had received four of more 
cycles of BEACOPPescalated. As a result, the risk for the 
development  of  t-MDS/t-AML  was  significantly 
increased for patients treated with four or more cycles 
of escalated BEACOPP while the risk for patients from 
the  other  groups  was  comparable  (1.5%  vs  0.5%  vs 
0.3%). In comparison with the report from Josting and 
co-workers, a higher portion of patients included in the 
update analysis had received aSCT for the treatment of 
t-MDS/t-AML. These mostly young patients who had 
been  eligible  for  intensive  induction  and/or 
conditioning  protocols  prior  to  aSCT  showed  an 
improved  outcome.  However,  overall  outcome  after 
diagnosis  of  t-MDS/t-AML  was  still  poor  with  a 
median survival of 7.2 months for the whole patient 
group.
15
The improved treatment results reported for selected
patients  eligible  for  aSCT  are  in  line  with  a  recent 
analysis from Kayser and colleagues. The outcome of 
200 patients with t-AML who were previously treated 
for different solid and hematologic malignancies was 
compared with the treatment results of 2653 patients 
with de novo AML. Relapse-free survival and OS were 
inferior  in  patients  with  t-AML with  4-year  rates  of 
24.5%  and  25.5%,  respectively,  compared  to  37.9% 
and  39.5%,  respectively,  for  patients  with  de  novo
AML.  However, 40  of the 200  patients with t-AML 
included  in  the  analysis  received  aSCT  in  first 
complete remission and had a 4-year OS rate of 42.6%. 
This is still inferior when compared with patients with 
de novo AML undergoing aSCT who had a 4-year OS 
rate of 58.0% but significantly better than reported in 
older analyses on t-AML.
16
A similar analysis was performed by Litzow and co-
workers. The outcome of 545 patients with t-AML and 
323  patients  with  t-MDS  who  underwent  allogeneic 
bone marrow or stem cell transplantation between 1990 
and 2004 was analyzed. Disease-free survival and OS 
rates were 32% and 37%, respectively, at one year and 
21% and 22%, respectively, at four years. At first sight, 
these  results  appear  inferior  in  comparison  with  the 
data reported by Kayser and colleagues. However, the 
analyses are difficult to compare since Litzow and co-
workers  also  included  patients  who  received  an 
allograft  in  the  early  1990´s.  Results  achieved  with 
aSCT  at  that  time  are  not  comparable  with  those 
observed today.
17    
In  conclusion,  the  prognosis  of  patients  with  t-
MDS/t-AML has apparently improved within the past 
years. The main reason for this improvement consists 
in the increased availability and the optimized use of 
aSCT. 
Prevention of late effects including t-MDS/t-AML. 
With current standard approaches consisting of multi-
agent  chemotherapy  optionally  combined  with  RT, 
patients  diagnosed  with  HL  achieve  long-termMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2: Freedom from treatment failure and overall survival among patients with t-MDS/t-AML treated for Hodgkin lymphoma (adopted 
from Josting et al., J Clin Oncol, 2003)
remission and can be considered cured in  more than 
80% of cases.
3-5 Since remission  rates can hardly be 
improved, the  reduction  of  acute  and  long-term  side 
effects including secondary hematologic malignancies 
such  as  t-MDS/t-AML  has  become  increasingly 
important in recent years.
Ongoing clinical trials aim at reducing the risk to 
develop late sequelae including t-MDS/t-AML without 
compromising  treatment  efficacy.  Thus,  response-
adapted  treatment  strategies  are  being  evaluated. 
Positron  emission  tomography  (PET)  is  currently 
considered  the  most  promising  tool  to  distinguish 
between patients who are sufficiently treated with less 
aggressive  approaches  and  patients  who  require 
standard or even intensified protocols.
Within  the  GHSG  HD15  trial,  patients  with 
advanced  HL  were  initially  randomized  to  receive 
either eight cycles of BEACOPPescalated, six  cycles of 
BEACOPPescalated or  eight  cycles  of  BEACOPP-14. 
Then,  a  PET  scan  was  performed  in  patients  with 
residual lymphoma larger than 2.5 cm. Localized RT 
was  confined  to  those  patients  with  PET-positive 
residual  disease.  As  a  result,  the  negative  predictive 
value  of  PET  defined  as  the  proportion  of  PET-
negative  patients  without  progression,  relapse  or  RT 
within 12 months was 94.6%. Thus, it appears possible 
to  restrict  consolidating  RT  to  patients  with  larger 
PET-positive  residual  lymphoma  after  intensive 
chemotherapy with escalated BEACOPP.
18
In  the  ongoing  GHSG  follow-up  trial,  HD18 
(NCT0051554),  all  patients  receive  two  cycles  of 
escalated  BEACOPP  before  an  interim  PET  is 
conducted.  Then,  patients  with  a  negative  PET  are 
randomized between the standard treatment consisting 
of six further cycles of BEACOPPescalated and a reduced 
treatment  consisting  of  only  two  further  cycles  of 
BEACOPPescalated while  patients  with  insufficient 
metabolic  response  are  randomized  between  the 
standard  treatment  and  an  intensified  protocol 
consisting of six further cycles of escalated BEACOPP 
supplemented by the anti-CD20 antibody rituximab in 
the last five cycles. 
In  a  trial  conducted  by  an  Italian  Group 
(NCT00795613), treatment for patients with advanced 
HL is also stratified according to early interim PET. 
All  patients  initially  receive  two  cycles  of  ABVD. 
Then,  a  PET  scan  is  performed.  Patients  without 
detection  of  active  disease  continue  treatment  with 
ABVD  while  patients  with  PET-positive  residual 
lymphoma  switch  to  the  more  intensive 
BEACOPPescalated protocol for the rest of treatment. 
In addition to the trials mentioned, further studies 
investigating response-adapted strategies with the aim 
to  reduce  treatment  intensity  in  patients  with  good 
initial response on the one hand and intensify treatment 
in  high-risk  patients  on  the  other  hand  are  currently 
recruiting patients.
Another possible way to reduce the incidence of t-
MDS/t-AML may consist in choosing the HL treatment 
according  to  the  patient´s  predisposition  to  develop 
therapy-related  secondary malignancies. However, no 
susceptibility factors such as certain single nucleotide 
polymorphisms  (SNP)  predicting  the  risk  of  the 
individual patient to develop t-MDS/t-AML have been 
identified  to  date.  Analyses  of  larger  patient  series 
addressing this issue appear necessary but are pending.  Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Summary.  Within  the  past  decades,  HL  has  turned 
from  an  incurable  disease  to  one  of  the  adult 
malignancies  with  best  cure  rates.  Thus,  treatment 
efficacy can hardly be improved and the prevention of 
acute and long-term toxicity including lung and heart 
failure,  temporary  or  permanent  infertility  and 
secondary  malignancies  including  t-MDS/t-AML  has 
become one of the major challenges. 
Currently  ongoing  trials  aim  at  reducing  the 
cumulative  treatment  toxicity  by  using  response-
adapted strategies. Low-risk and high-risk patients are 
being  distinguished  according  to  the  result  of  an 
interim PET. Once valid results from these trials will 
be  available,  treatment  stratification  based  on  early 
interim  PET  might  become  standard  of  care  in  HL 
therapy. Thus, cumulative chemotherapy and radiation 
doses could decrease in a relevant portion of patients.
Patients  who  are  diagnosed  with  t-MDS/t-AML 
after HL treatment still have a poor prognosis although 
substantial therapeutic improvements were made in the 
past decade. These improvements are mainly due to the 
increased availability and the optimized use of aSCT. 
About  20%  to  40%  of patients  with  t-MDS/t-AML 
achieve  long-term  remission  when  treated  with 
aSCT.
16-17
Conclusion. The  major  goals  in  connection  with  t-
MDS/t-AML after treatment for HL consist in 1) the 
establishment  of risk-adapted treatment  strategies  for 
HL  and  2)  the  further  optimization  of  treatment for 
patients diagnosed with t-MDS/t-AML.
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